Advertisement
Advertisement
IRWD
Ironwood Pharmaceuticals, Inc. - Class A
4.32
USDSponsored
+0.02
+0.47%
Aug 12, 16:00 UTC -4
Closed
Pre-Market
4.44
+0.12
+2.87%
IRWD Earnings Reports
Positive Surprise Ratio
IRWD beat 21 of 42 last estimates.
50%
Next Report
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$122.39M
/$0.36
Implied change from Q2 26 (Revenue/ EPS)
+8.27%
/+16.13%
Implied change from Q3 25 (Revenue/ EPS)
+0.27%
/+50.00%
Ironwood Pharmaceuticals, Inc. - Class A earnings per share and revenue
On Aug 06, 2026, IRWD reported earnings of 0.31 USD per share (EPS) for Q2 26, missing the estimate of 0.36 USD, resulting in a -14.62% surprise. Revenue reached 113.04 million, compared to an expected 117.14 million, with a -3.50% difference. The market reacted with a +2.65% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of 0.36 USD, with revenue projected to reach 122.39 million USD, implying an increase of 16.13% EPS, and increase of 8.27% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Harrow, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.34
Surprise
-85.19%
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
Silence Therapeutics Plc - ADR
Report Date
Aug 10, 2026 For Q2 26
Estimate
-Actual
-$0.26
Surprise
-
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
Heron Therapeutics, Inc.
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.01
Actual
-$0.03
Surprise
-394.12%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
Oruka Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.52
Actual
-$0.55
Surprise
-4.62%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
FAQ
What were Ironwood Pharmaceuticals, Inc. - Class A's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Ironwood Pharmaceuticals, Inc. - Class A reported EPS of $0.31, missing estimates by -14.62%, and revenue of $113.04M, -3.5% below expectations.
How did the market react to Ironwood Pharmaceuticals, Inc. - Class A's Q2 2026 earnings?
The stock price moved up 2.65%, changed from $4.15 before the earnings release to $4.26 the day after.
When is Ironwood Pharmaceuticals, Inc. - Class A expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for Ironwood Pharmaceuticals, Inc. - Class A's next earnings report?
Based on 4
analysts, Ironwood Pharmaceuticals, Inc. - Class A is expected to report EPS of $0.36 and revenue of $122.39M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement